Modern Vaccines Adjuvants & Delivery Systems

12-14 September 2017, Crowne Plaza Hotel, Porto, Portugal

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Final Conference Programme | Thursday 14th September 2017

SESSION 8:
ADJUVANTS ACTIVITY

Moderator: Ken Ishii
(NIBIOHN/Osaka University, Osaka, Japan)

09.00-09.20
‘Characterization of the adjuvant activity of linear polyacrylates’
Jean Haensler1, Marie Garinot1, Yuanqing Liu1, Fabienne Piras1, Virginie Courtois1, Premkumar Dinadayala1, Elodie Belnoue2, Floriane Auderset2, Beatris Mastelic-Gavillet2 and Claire-Anne Siegrist2
(1 Sanofi Pasteur, Marcy l’Etoile, France; 2 CMU- University of Geneva, Geneva, Switzerland)

09.20-09.40
‘Adjuvant properties of the novel toll-like receptor 7 and 8 agonist 3M-052’
Mark Tomai
(3M Company, St Paul, Minnesota, USA)

09.40-10.00
‘Effect of QS21 and aluminum hydroxide gel on physical and adjuvant properties of Army liposome formulations’
Zoltan Beck1,2, Gary Matyas2, Carl Alving2 and Victoria Polonis3
(US Military HIV Research Program: 1 Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA; 2 Laboratory of Adjuvant and Antigen Research; 3 Laboratory of Vaccine Immunology, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)

10.00-10.20
‘Selection of a novel MPLA and QS-21 containing liposomal adjuvant, ALFQ, for a circumsporozoite protein based malaria vaccine, FMP013’
Sheetij Dutta1, Christopher J. Genito1, Zoltan Beck3, Alicia D. Cawlfield2, Timothy W. Phares1, Norman C. Waters1, Gary R. Matyas3, David E. Lanar1 and Carl R. Alving3
(1 Malaria Vaccine Branch and 2 Department of Veterinary Medicine, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; 3 Laboratory of Adjuvant and Antigen Research, US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)

10.20-10.40
‘Key role of QS21 and NK/CD4 T cell interplay in AS01 mode of action’
S. Goriely, M. Coccia, Sofia Buonocore and Arnaud Didierlaurent
(GSK Vaccines, Rixensart, Belgium)

10.40-11.00
‘Use of IFN-ë2 as an intradermal adjuvant confers potent systemic and mucosal immune responses in the mouse model’
Lisa Mills
(Emory University, Atlanta, Georgia, USA)

11.00-11.15
Coffee Break & Posters Breakdown

SESSION 9:
FORMULATION & DELIVERY

Moderator: Manmohan Singh
(Takeda vaccines Inc., Cambridge, Massachusetts, USA)

11.15-11.35
‘Outer membrane vesicles as delivery system for Bordetella pertussis antigens’
R. Raeven1, J. Brummelman2, J. Pennings2, E. van Riet1, C. van Els2, W. Han2, B. Metz1 and G. Kersten1
(1 Institute for Translational Vaccinology, Bilthoven, The Netherlands; 2 Institute for Public Health and the Environment, Bilthoven, The Netherlands)

11.35-11.55
‘Optimization of formulation and delivery systems for in vivo transfer of DNA-based immunoprophylactics’
Trevor R.F. Smith1, Katherine Schultheis1, Stephanie Ramos1, Nina Schommer1, Jingjing Jiang1, Bryan Yung1, Jian Yan1, Ami Patel2, Sarah Elliot2, Kar Muthumani2, Megan Wise2, Kim A. Kraynyak2, Laurent Humeau1, David B. Weiner2, Niranjan Y. Sardesai1 and Kate E. Broderick1
(1 Inovio Pharmaceuticals, Inc., Plymouth Meeting, Pennsylvania, USA; 2 The Wistar Institute of Anatomy & Biology, Philadelphia, Pennsylvania, USA)

11.55-12.15
‘Breaking the barrier of proprietary adjuvants and delivery systems’
Kenneth Bertram
(US Army Medical Research and Material Command, Fort Detrick, Maryland, USA)

12.15-12.35
‘Increasing antigen presenting cells at the injection site improves SAM vaccine efficacy’

Cristina Manara, Michela Brazzoli, Diego Piccioli, Marianna Taccone, Ugo D’Oro, Domenico Maione and Elisabetta Frigimelica
(GSK Vaccines s.r.l., Siena, Italy)

12.35-12.40
Closing Remarks

12.40
Lunch & Departure

* This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.

 

MVADS 2017 Delegates

Login details will be supplied after you have registered for the event.


MVADS 2017 Sponsors

  • iZon Science
  • CureVac
  • BIA Separations
  • Mucosis
  • Janssen
  • Precision Vaccines Program
  • Vaxart
  • Brenntag
  • Aldevron
  • Inovio
  • National Institute of Allergy and Infectious Diseases
  • EVI
  • Mymetics
  • Sanofi Pasteur
  • NatureGeneTherapy.com
  • Novavax
  • Bill and Melinda Gates Foundation
  • BioAster
  • VisMederi
  • Seppic
  • DNAvaccine.com
  • Pfizer
  • Univac
  • IDRI
  • BPRC
  • Eurocine Vaccines
  • Matrivax

MVADS 2017 Downloads

MVADS 2017 Leaflet

MVADS 2017 Mailing List

Name
E-mail Address
What is 3+2-1?